Venclexta

News

AbbVie/Roche's Venclexta fails in confirmatory AML trial

AbbVie and Roche's Venclexta has failed to significantly improve overall survival in an acute myeloid leukaemia (AML) trial that was supposed to confirm its efficacy.

News

Roche and AbbVie’s Venclexta approved in CLL

Roche and AbbVie’s Venclexta (venetoclax) has been approved by the FDA in combination with Roche’s Gazyva (obinutuzumab) for the treatment of people with previously untreated chronic lympho

News

AbbVie/Roche seek first-line CLL use for Venclexta combo

AbbVie and Roche’s Venclexta is making headway as a second-line chronic lymphocytic leukaemia (CLL) treatment, and a new US filing could extend its use into the first-line setting.

News

AbbVie, Roche eye first-line use of Venclexta in leukaemia

AbbVie and Roche’s Venclexta has hit the mark in a combination trial that could help it move into the treatment-naive chronic lymphocytic leukaemia (CLL) arena.

Clinical

AbbVie/Roche's Venclexta produces complete remission in 10% ...

AbbVie/Roche's Venclexta (venetoclax) has produced a high overall response rate in chronic lymphocytic leukaemia patients with the 17p deletion mutation, a sub-group who do not respond well

AbbVie/Roche's Venclexta fails in confirmatory AML trial

Roche and AbbVie’s Venclexta approved in CLL

AbbVie/Roche seek first-line CLL use for Venclexta combo

AbbVie, Roche eye first-line use of Venclexta in leukaemia

AbbVie/Roche's Venclexta produces complete remission in 10% ...

NHS staff 'feel unprepared for digital transformation'

How to meet your physicians where they are online

Venclexta

Editor's Picks